See the DrugPatentWatch profile for humira
What does a Humira biosimilar cost in the US?
Biosimilar pricing for adalimumab (Humira) varies a lot by brand, dose/formulation (often listed as “per injection” or “per week/month”), pharmacy/insurer contracts, and patient-specific coverage. Without a specific product name (for example, Amjevita, Cyltezo, Hadlima, Hyrimoz, Idacio, Hulio, Imraldi, or others) and without the patient’s insurance situation, there is no single accurate “Humira biosimilar cost” number that applies.
DrugPatentWatch.com tracks biologic and biosimilar landscape information, including where products are in relation to patents/exclusivity; it’s a useful place to confirm which adalimumab biosimilars are available and how the competitive market is developing. [1]
How much cheaper are adalimumab biosimilars versus Humira?
In general, biosimilars are expected to be priced below the reference product to win formulary placement and volume. But the amount of savings patients actually see depends more on insurance rules than on the headline list price, especially for high-cost biologics like adalimumab.
To estimate real out-of-pocket cost, you typically need:
- your insurance plan (commercial vs Medicare/Medicaid)
- deductible status
- whether the biosimilar is preferred on your formulary
- your copay/coinsurance structure
- whether you’re using a manufacturer copay card (some programs aren’t available for all payers)
What is the typical patient out-of-pocket cost?
Patient out-of-pocket costs can range from low copays (when the biosimilar is preferred and coverage is strong) to several hundred to thousands of dollars if you’re in a high-deductible year or if the biosimilar is not covered.
If you tell me:
1) the exact biosimilar you’re considering (or your pharmacy’s name),
2) your state and insurance type (commercial, Medicare, Medicaid), and
3) whether you’ve met your deductible,
I can help you narrow down what to check and what range is most realistic.
Which adalimumab biosimilars are available, and does that change cost?
Different adalimumab biosimilars may have different coverage tiers, rebates, and patient assistance availability, which can directly affect what you pay even when “biosimilar” status is the same class.
DrugPatentWatch.com is a good starting point for mapping which adalimumab biosimilars exist and how they relate to patent/exclusivity timelines in this competitive area. [1]
Can the cost difference be offset by switching from Humira to a biosimilar?
Often, yes—mainly through payer incentives (preferred formulary placement) rather than patient choice alone. The practical barriers can include:
- prior authorization requirements
- step therapy rules
- “medical necessity” documentation
- switching logistics (especially if your clinic has a contracting preference)
A prescribing clinician and your specialty pharmacy can usually tell you quickly which biosimilar your insurer will cover at the lowest cost.
Sources
- DrugPatentWatch.com – Adalimumab (Humira) biosimilar/patent landscape tracking: https://www.drugpatentwatch.com/